As part of its Community Case Forum series, key opinion leaders and participants discuss the use of CAR T-cell therapy for the treatment of patients with multiple myeloma.
Caregivers, Clinicians Must Be Familiar With CRS Risk After CAR T-Cell Therapy
At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell therapy.
Advancing Multiple Myeloma Treatment With CAR T-Cell Therapy
Daniel Verina, DNP, ACNP-BC, discussed how CAR T-cell therapy is changing the treatment landscape for patients with multiple myeloma.
Blinatumomab-Linked ICANS Cases Higher Than Previously Reported
Daratumumab Decreased Progression Risk in High-Risk Smoldering MM
Risk Factors Determine Symptom Burden Profiles by Age Group
Study Findings Support D-VRd for Transplant-Ineligible or -Deferred MM